Raquel

Sperm-associated antigen 5 (SPAG5) represents a novel oncogene in estrogen receptor (ER)–positive luminal-B breast cancer. The authors of this study evaluated the association of SPAG5 gene and protein expression and treatment response in 12,270 patients with ER-positive breast cancer. Overexpression was associated with higher odds of a pathologic complete response. Furthermore, among women with SPAG […]

Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. We observed that most of

Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of Piqray® (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer with

The U.S. Food and Drug Administration (FDA), approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or “rearranged during transfection”). Retevmo is the first

KRAS mutations are the most common oncogenic event in colorectal cancer (CRC) progression and their occurrence is associated with lack of response to anti epidermal growth factor receptor (EGFR) targeted therapies. Using preclinical models and patients’ samples we recently reported that the emergence of KRAS mutations but also KRAS amplification is associated with acquired resistance

As part of Project Orbis, the U.S. Food and Drug Administration approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can’t be removed with surgery, or has spread to other parts of the body, including the brain, and who have received

The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia have been widely adopted, but have not yet been validated in large cohorts of AML patients. We studied 1116 newly diagnosed AML patients (age range, 18-86 years) who had received induction chemotherapy. Among 771 patients not selected by genetics, the

The authors of this review provide an overview of data regarding HER2 as a predictive biomarker and target for treatment among patients with metastatic colorectal cancer (mCRC). The use of anti-EGFR monoclonal antibodies has been associated with improved outcomes among patients with RAS wild-type mCRC, but not all patients respond to therapy. The prognosis of

Current clinical practice includes testing for microsatellite instability (MSI) status, KRAS mutation status, and/or BRAF mutation status in a subset of patients with colorectal cancer (CRC) based on reported family history and stage at diagnosis. Patients with type 2 CRC had the poorest prognosis, particularly with respect to disease-specific survival (DSS). Regardless of other tumor

TRK fusion–positive solid tumors represent a unique molecular subgroup of tumors that are susceptible to larotrectinib therapy. This pooled analysis of three phase I/II trials was designed to evaluate the benefit of larotrectinib in patients with TRK fusion–positive solid tumors. The objective response rate was 79%, with a complete response rate of 16%. The safety